









Markets
/
Stocks
/
nasdaq-vcyt
/

Veracyte Inc

VCYT

34.110USD

+0.880+2.65%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.68BMarket Cap

101.80P/E TTM



Veracyte Inc

34.110

+0.880+2.65%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

5 / 506

Overall Ranking

56 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

41.222

Target Price

+24.05%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 50.32% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 24.14M.%!(EXTRA int=2)

Overvalued

The company’s latest PE is 99.74, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 84.22M shares, decreasing 2.21% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 8.08M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.01, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 130.16M, representing a year-over-year increase of 13.75%, while its net profit experienced a year-over-year increase of 117.09%.

Score

Industry at a Glance

Previous score

8.01

Change



Financials

9.73

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.71

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.62

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 5.01, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 97.16, which is -122.83% below the recent high of -22.18 and 149.49% above the recent low of -48.08.

Score

Industry at a Glance

Previous score

5.01

Change

-0.08

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 5/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.36, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Veracyte Inc is 42.00, with a high of 53.00 and a low of 28.00.

Score

Industry at a Glance

Previous score

8.36

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

41.222

Target Price

+24.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Veracyte Inc

VCYT

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.24, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 34.99 and the support level at 29.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.24

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.192

Buy

RSI(14)

67.015

Neutral

STOCH(KDJ)(9,3,3)

81.336

Buy

ATR(14)

1.277

High Vlolatility

CCI(14)

195.303

Buy

Williams %R

11.246

Overbought

TRIX(12,20)

0.592

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

32.664

Buy

MA10

32.133

Buy

MA20

31.227

Buy

MA50

28.224

Buy

MA100

28.108

Buy

MA200

32.837

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 107.53%, representing a quarter-over-quarter decrease of 1.95%. The largest institutional shareholder is The Vanguard, holding a total of 8.08M shares, representing 10.27% of shares outstanding, with 2.83% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

8.25M

+0.64%

Fidelity Management & Research Company LLC

6.17M

+205.06%

Artisan Partners Limited Partnership

5.24M

-20.60%

BlackRock Institutional Trust Company, N.A.

6.21M

-0.67%

ARK Investment Management LLC

Star Investors

3.21M

-8.20%

Wellington Management Company, LLP

3.85M

-5.67%

State Street Global Advisors (US)

3.16M

+8.50%

Dimensional Fund Advisors, L.P.

2.91M

+0.98%

ArrowMark Colorado Holdings, LLC

3.23M

+4.76%

Geode Capital Management, L.L.C.

1.93M

+5.16%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.25, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.